Duncan Richards
Overview
Explore the profile of Duncan Richards including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hobbs F, Gbinigie-Thompson O, Shanyinde M, Yu L, Harris V, Dorward J, et al.
J Infect
. 2024 Aug;
89(4):106248.
PMID: 39216829
Background: Evidence for the effect of favipiravir treatment of acute COVID-19 on recovery, hospital admissions and longer-term outcomes in community settings is limited. Methods: In this multicentre. open-label, multi-arm, adaptive...
2.
Brady S, Mott A, Carlisle K, Abhishek A, Adamson J, Coates L, et al.
BMJ Open
. 2024 Jun;
14(6):e084997.
PMID: 38910007
Introduction: Biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionised the treatment of inflammatory arthritis (IA). However, many people with IA still require planned orthopaedic surgery to reduce pain and improve function....
3.
Kawano-Dourado L, Kulkarni T, Ryerson C, Rivera-Ortega P, Baldi B, Chaudhuri N, et al.
Thorax
. 2024 Mar;
79(8):788-795.
PMID: 38448221
Background: Fibrotic interstitial lung diseases (fILDs) are a heterogeneous group of lung diseases associated with significant morbidity and mortality. Despite a large increase in the number of clinical trials in...
4.
Hayward G, Yu L, Little P, Gbinigie O, Shanyinde M, Harris V, et al.
J Infect
. 2024 Mar;
88(4):106130.
PMID: 38431155
Background: The evidence for whether ivermectin impacts recovery, hospital admissions, and longer-term outcomes in COVID-19 is contested. The WHO recommends its use only in the context of clinical trials. Methods:...
5.
Weeratunga P, Denney L, Bull J, Repapi E, Sergeant M, Etherington R, et al.
Nat Commun
. 2023 Nov;
14(1):7216.
PMID: 37940670
Single cell spatial interrogation of the immune-structural interactions in COVID -19 lungs is challenging, mainly because of the marked cellular infiltrate and architecturally distorted microstructure. To address this, we develop...
6.
Higham H, Morgan L, Cooper C, Marshall J, Mawer A, Jackson S, et al.
Br J Clin Pharmacol
. 2023 Oct;
90(7):1586-1599.
PMID: 37903635
Aims: The influence of human factors on safety in healthcare settings is well established, with targeted interventions reducing risk and enhancing team performance. In experimental and early phase clinical research...
7.
Ooms A, Al-Mossawi H, Bennett L, Bogale M, Bowness P, Francis A, et al.
BMJ Open
. 2023 Sep;
13(9):e078539.
PMID: 37770264
Introduction: Psoriatic arthritis (PsA) affects around 150 000 people in the UK of whom around 50% require treatment with biologics. The most used biologics for PsA target tumour necrosis factor...
8.
Gbinigie O, Ogburn E, Allen J, Dorward J, Dobson M, Madden T, et al.
BMJ Open
. 2023 Aug;
13(8):e069176.
PMID: 37550022
Introduction: There is an urgent need to determine the safety, effectiveness and cost-effectiveness of novel antiviral treatments for COVID-19 in vaccinated patients in the community at increased risk of morbidity...
9.
Drennan P, Karponis D, Richards D, Coles M, Fullerton J
Clin Transl Sci
. 2022 Nov;
16(3):357-382.
PMID: 36420645
Experimental exposure of healthy volunteers to the T-cell dependent neoantigen keyhole limpet hemocyanin (KLH) permits the evaluation of immunomodulatory investigational medicinal product (IMP) pharmacology prior to the recruitment of patient...
10.
Scannell J, Bosley J, Hickman J, Dawson G, Truebel H, Ferreira G, et al.
Nat Rev Drug Discov
. 2022 Oct;
21(12):915-931.
PMID: 36195754
Successful drug discovery is like finding oases of safety and efficacy in chemical and biological deserts. Screens in disease models, and other decision tools used in drug research and development...